Although the efficacy of RLN2 in acute heart failure has not been confirmed, various preclinical studies have confirmed its promising antifibrotic effects in fibrosis-related diseases, such as hypertrophic cardiomyopathy (48, 49), hepatic fibrosis (50), and renal fibrosis (48). This evidence concerns the gene RLN2 and hypertrophic cardiomyopathy.